A Phase II Study With Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) For Newly Diagnosed Multiple Myeloma
Year: 2013
Type: conference-abstract
Study design: Clinical Trial
Source: Blood
Authors: Sara Bringhen, Chiara Cerrato, Maria Teresa Petrucci, Mariella Genuardi, Fabiana Gentilini, Concetta Conticello, Stefania Oliva, Lucia Pantani, Massimo Offidani, Carmela Palladino, Giulia Benevolo, Vittorio Montefusco, Monica Astolfi, Oreste Villani, Agostina Siniscalchi, Alberto Rocci, Lorenzo De Paoli, Mario Boccadoro, Pieter Sonneveld, Antonio Palumbo
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: carfilzomib, multiple myeloma, newly diagnosed multiple myeloma, elderly patients, proteasome inhibitors, cyclophosphamide, dexamethasone, combination chemotherapy, near complete response, complete response, progression-free survival, overall survival, frailty, treatment toxicity, maintenance therapy, transplant-ineligible patients, geriatric assessment, frailty index, Charlson Comorbidity Index
Open Access status: closed
OpenAlex ID: W2646510
